Journal Article > ReviewFull Text
Infect Dis Clin North Am. 1 June 2018; Volume 32 (Issue 2); 425-445.; DOI:10.1016/j.idc.2018.02.010
Applegate TL, Farjardo E, Sacks JA
Infect Dis Clin North Am. 1 June 2018; Volume 32 (Issue 2); 425-445.; DOI:10.1016/j.idc.2018.02.010
The world has embraced the call for global elimination of hepatitis C virus by 2030. The unprecedented speed of therapeutic development and increased access to direct-acting antivirals has made elimination a possibility. We must screen hundreds of millions of people to diagnose and treat those currently infected. Global access to hepatitis C virus diagnostics will be a keystone to success. Key challenges must be overcome and systems optimized to ensure widespread access to existing diagnostics. Although promising technologies may soon transform the landscape, innovative strategies are needed to stimulate investment and accelerate the development of point-of-care hepatitis C virus diagnostics.